ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

Cephalalgia : an International Journal of Headache
David W DodickRobert A Lenz

Abstract

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention. Methods In this randomized, double-blind, placebo-controlled, phase 3 study, 577 adults with episodic migraine were randomized to placebo or 70 mg erenumab; 570 patients were included in efficacy analyses. Primary endpoint was change in monthly migraine days. Secondary endpoints were ≥50% reduction in monthly migraine days, change in acute migraine-specific medication treatment days, and ≥5-point reduction in Physical Impairment and Impact on Everyday Activities domain scores measured by the Migraine Physical Function Impact Diary. All endpoints assessed change from baseline at month 3. Results Patients receiving erenumab experienced -2.9 days change in monthly migraine days, compared with -1.8 days for placebo, least-squares mean (95% CI) treatment difference of -1.0 (-1.6, -0.5) ( p < 0.001). A ≥ 50% reduction in monthly migraine days was achieved by 39.7% (erenumab) and 29.5% (placebo) of patients (OR:1.59 (95% CI: 1.12, 2.27) ( p = 0.010). Migraine-specific medication treatment days were re...Continue Reading

References

Dec 1, 1987·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·L EdvinssonR Uddman
Dec 22, 1998·Neurología : publicación oficial de la Sociedad Española de Neurología·J M Laínez Andrés
May 8, 2002·Cephalalgia : an International Journal of Headache·L H LassenJ Olesen
Jul 9, 2002·Cephalalgia : an International Journal of Headache·P-H M van der Kuy, J J H M Lohman
Dec 4, 2003·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M KosinskiS Tepper
Feb 26, 2004·JAMA : the Journal of the American Medical Association·Jan Lewis BrandesUNKNOWN MIGR-002 Study Group
Jan 22, 2005·Cephalalgia : an International Journal of Headache·K A PetersenJ Olesen
Jan 31, 2007·Neurology·R B LiptonUNKNOWN AMPP Advisory Group
Apr 25, 2007·European Journal of Pain : EJP·Ana MacedoMagí Farré
Feb 27, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·James AdelmanJoseph Hulihan
Feb 23, 2010·Lancet Neurology·Peter J Goadsby, Till Sprenger
Sep 8, 2010·Nature Reviews. Neurology·Tony W HoPeter J Goadsby
Jun 19, 2013·Cephalalgia : an International Journal of Headache·UNKNOWN Headache Classification Committee of the International Headache Society (IHS)
Jan 1, 2014·Journal of Managed Care Pharmacy : JMCP·Zsolt HeppSepideh F Varon
Jun 5, 2015·Current Pain and Headache Reports·Elizabeth K SengRichard B Lipton
Nov 25, 2017·The New England Journal of Medicine·Peter J GoadsbyRobert A Lenz

❮ Previous
Next ❯

Citations

Jun 16, 2018·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Michail VikelisAlan M Rapoport
Aug 4, 2018·Continuum : Lifelong Learning in Neurology·Todd J Schwedt
Sep 22, 2018·Pain Management·Sameer JainStephen D Silberstein
Nov 30, 2018·Expert Opinion on Emerging Drugs·Giorgio LambruPaolo Martelletti
Jan 8, 2019·Expert Review of Neurotherapeutics·Lucas Hendrik OvereemUwe Reuter
Mar 1, 2019·The Annals of Pharmacotherapy·Scott G GarlandJohn G Gums
Mar 6, 2019·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Stewart J Tepper
Jan 17, 2019·Clinical Pharmacology and Therapeutics·Hsiangkuo YuanStephen D Silberstein
Mar 15, 2019·Current Treatment Options in Neurology·Sameer Jain, Stephen D Silberstein
May 31, 2019·Cephalalgia : an International Journal of Headache·Messoud AshinaDaniel D Mikol
Jul 23, 2019·Headache·Jonathan M Borkum
Apr 21, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Peter J GoadsbySheena K Aurora
Aug 9, 2019·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Kathleen B Digre
Jul 10, 2019·Cephalalgia : an International Journal of Headache·Eloísa Rubio-BeltránAntoinette MaassenVanDenBrink
Sep 26, 2019·Expert Opinion on Biological Therapy·Bianca RaffaelliUwe Reuter
Nov 7, 2019·Current Pharmaceutical Design·Cinzia CavestroEugenia Rota
Sep 27, 2019·CNS Drugs·Calvin Chan, Peter J Goadsby
Nov 26, 2019·Journal of Pain & Palliative Care Pharmacotherapy·Brianna HensonChris Herndon
Jul 26, 2019·Neurology. Clinical Practice·Peter J Goadsby
Feb 1, 2020·Expert Opinion on Therapeutic Targets·Anne-Sophie WattiezAndrew F Russo
Jun 11, 2019·Expert Opinion on Biological Therapy·Stephen D SilbersteinPaul P Yeung
Apr 1, 2020·Headache·Christina L SzperkaRobert E Shapiro
May 22, 2020·Expert Review of Neurotherapeutics·Eleonora De MatteisSimona Sacco
Jun 3, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Pablo IrimiaCarlos Rubio-Terrés
Sep 26, 2019·Cephalalgia : an International Journal of Headache·Edita NavratilovaFrank Porreca
Aug 15, 2020·Cephalalgia : an International Journal of Headache·Saad KanaanRebecca Burch
Aug 20, 2020·Expert Opinion on Drug Safety·Eduardo Rivera-MancillaAntoinette MaassenVanDenBrink
Jul 23, 2020·Der Nervenarzt·Marcel GebhardtUwe K Zettl
Jul 18, 2018·Current Pain and Headache Reports·Kate W Grimsrud, Rashmi B Halker Singh
Feb 28, 2019·Arquivos de neuro-psiquiatria·Abouch V KrymchantowskiCarla da Cunha Jevoux

❮ Previous
Next ❯

Software Mentioned

ARISE
STRIVE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.